Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Illumina, Inc. - Common Stock (NQ: ILMN )

136.67 -0.70 (-0.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Illumina, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
21 Stocks Moving in Tuesday's Pre-Market Session
Gainers OneSmart International Education Group Limited (NYSE: ONE) rose 39.1% to $0.2701 in pre-market trading. OneSmart International Education Group received notification from... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Higher Ahead Of Powell
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones dipped more than 160 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
5 Stocks To Watch For January 11, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects TD SYNNEX Corporation (NYSE: SNX) to report quarterly earnings at $2.67 per share on revenue of $... 
Via Benzinga
Start Of The Week
British property (real estate) stocks fell today. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Inari Medical (NASDAQ:NARI) stock... 
Via Benzinga
Why Jim Cramer Likes Illumina And Enterprise Products Partners
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Illumina, Inc. (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With SomaScan For Accelerating... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
Why Jim Cramer Likes Illumina, SoFi And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said SoFi Technologies, Inc’s (NASDAQ: 
Via Benzinga
Bionano Genomics Proves Not Everything Genetic is Gold
Bionano sells a $150,000 machine called Saphyr that does genetic mapping. It's a solid device, but its future remains in the future, as do BNGO stock fortunes. 
Via InvestorPlace
10x Genomics Stock: Bull vs. Bear
After a hot start, the stock has recently lagged the market. Is now a good time to buy? 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Wait for Bionano Stock to Fall Further Before Buying
BNGO stock is breaking down following the latest earnings report, and there are no major catalysts to push shares up in the short term. 
Via InvestorPlace
Following Rough Year, Is Burning Rock Set To Turn The Corner?
Key Takeaways: Burning Rock expects fourth-quarter revenue to grow just 6% year-on-year due to latest Covid-related travel restrictions in China Cancer testing specialist’s... 
Via Benzinga
Europe To Layout Objections to Illumina-Grail Deal: Bloomberg
Illumina Inc (NASDAQ: ILMN) says the European Union will issue a list of objections tomorrow over the Company's $8B takeover of GRAIL, Bloomberg reports. Related... 
Via Benzinga
Illumina Clocks 40% Growth In Q3; Earnings Beat Expectations
Illumina Inc (NASDAQ: ILMN) reported Q3 revenues of $1.11 billion, +40% Y/Y, beating the consensus of $1.04 billion. Consolidated Product revenues were $978 million,... 
Via Benzinga
Topics Earnings
Exposures Financial
Illumina, inc (ILMN) Q3 2021 Earnings Call Transcript
ILMN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
After Its Grail Buyout, Illumina Beats Third-Quarter Expectations
Illumina stock inched higher late Thursday after the company beat forecasts. 
Via Investor's Business Daily
'Halftime Report' Final Trades From Oct. 25: Illumina, JPMorgan, And More
On CNBC’s "Halftime Report" f... 
Via Benzinga
Bet On Biopharma: Data, Digitization, Discovery
The after-effects of pandemic-era policies will be with us for some time — with many supply chains still experiencing significant disruption. The worst of this “scarring” will heal. But the... 
Via Talk Markets
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
Illumina Insider Sold $1.2M In Company Stock
Alexander Aravanis, SVP And Chief Technology Officer at Illumina (NASDAQ:ILMN), made a large insider sell on October 12, according to a new SEC filing. What Happened: A Form 4... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Why Shares of Ilumina Slumped 11.3% in September
The company's merger with GRAIL concerned investors. 
Via The Motley Fool
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
Some trends will persist for decades. 
Via The Motley Fool
UK's NHS Launches World's Largest Trial Of Blood Test For 50 Types
Britain's National Health Service (NHS) will begin the world's largest trial of Grail Inc's flagship Galleri blood test that can be used to detect... 
Via Benzinga
Illumina, Merck Join Hands For Homologous Recombination Deficiency CDx, Research Assay
Illumina Inc (NASDAQ: ILMN) and Merck & Co Inc (NYSE: MRK) provided more details on their partnership to develop and commercialize tests that gauge... 
Via Benzinga
Why Illumina Wants Grail Back So Badly
The gene-sequencing giant sees a huge opportunity in diagnostics. 
Via The Motley Fool
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. 
Via InvestorPlace
Workday And Lam Research Lead The QQQ
U.S. indices were trading higher Friday as investors eye Fed Chairman Powell's speech at the Jackson Hole Symposium and gauge Fed tapering policy. The Invesco QQQ Trust... 
Via Benzinga
Topics Economy
Exposures Interest Rates
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.